Plerixafor (Mozobil, AMD3100) is a bicyclam compound that reduces CD34 þ hematopoietic stem cells (HSCs) anchoring to the BM microenvironment through reversible inhibition of the SDF-1a/CXCR4 axis. 1, 2 It is synergistic with G-CSF, and when used together, this combination is useful in 'poor mobilizer' patients 3 or whenever a high overall volume of CD34 þ cells is needed, as with repetitive autotransplantation procedures. 4 Apart from gastrointestinal discomfort, the drug is deemed to be sufficiently safe for use, in pilot studies, as a single agent for PBSC mobilization in normal donors before allogeneic hematopoietic transplantation. 5, 6 The relatively short time required for the onset of measurable HSC mobilization to peripheral blood is also a distinct advantage with plerixafor. 6 Typically, an upsurge in peripheral blood CD34 þ cells is evident within 4-9 h after s.c. injection. This rapid effect is due to a nonreliance on modulation of cellular receptor or cytokine cascade, processes that are inherently slow. Based on its fast action, we have successfully used plerixafor for 'emergency' PBSC mobilization in a normal donor, for whom a routine BM harvest suddenly assumed disproportionate risk.
Case report
A 42-year-old man was diagnosed in February 2008 with AML (FAB type M4). His cytogenetic risk was considered to be 'intermediate.' He achieved CR with an initial 3 þ 7 course of anthracycline and cytosine arabinoside. After additional consolidation chemotherapy, an autologous PBSC harvest, mobilized with G-CSF, was cryopreserved for storage.
Allo-SCT from a 6/6 loci HLA-identical sister was also scheduled as post-remission treatment. The 45-year-old female donor showed no discernable pathology throughout a battery of tests, including chest X-ray, echocardiography, ECG and serological viral screening for HBV, HCV and HIV. She was thus jointly approved for HSC donation by a transplant physician and a transfusionist. A certified anesthetist, likewise, found her suitable for general anesthesia.
As it is the policy at our institution to target the BM preferentially for the first-choice harvest procedure, surgical harvest of the donor's marrow was scheduled for day 0 of the recipient conditioning regimen. The recipient was treated with a 'reduced-intensity' conditioning regimen of thiothepa 12 mg/kg and fludarabine 120 mg/m 2 , approved by the Ethics Committee Board of our hospital. However, after induction of anesthesia, tracheal intubation of the donor proved difficult. Her larynx was never successfully visualized, despite four intubation attempts and use of a video-laryngoscope.
By the fourth failed intubation attempt, pharyngeal bleeding with airway compromise and a 45-s episode of circulatory O 2 desaturation forced the harvest procedure to be abandoned. The donor was observed closely for several hours thereafter, but aside from mild pharyngodynia, her cardiorespiratory and neurological recoveries were complete. While under observation, all remaining means of rescue transplantation were discussed with the donor and recipient, including use of the autologous PBSC harvest already in storage.
A decision was eventually made, based on clinical considerations and after obtaining the authorization of the Ethical Committee Board, to attempt donor CD34 þ cell mobilization with a single administration of plerixafor and G-CSF in combination. Following the failed BM harvest, the donor received G-CSF (5 mcg/kg s.c.) at 1700 h, while plerixafor (240 mcg/kg s.c.) was given 6 h later, at 2300 h.
At 9 h after plerixafor dosing, the donor's WBC had reached 61.4 Â 10 9 /L and the CD34 þ cell count was 30 Â 10 6 /L. A 10-L apheresis session for PBSC collection was then conducted without any incident, using a COBE SPECTRA cell separator, for a yield of 2 Â 10 6 /CD34 þ cells per kg of recipient body weight In the immediate aftermath, the donor experienced only a moderate decrease in plt count (140 Â 10 9 /L) and mild, asymptomatic hypokalemia (3 mEq/L), which was treated by oral potassium supplementation.
Infusion of the PBSC harvest took place in the afternoon of day 1, representing a 24-h deviation from the delivery time that was originally scheduled. For immunosuppression, CYA 1 mg/kg c.i. was started on day À2, and a minidose of MTX was administered on days þ 2, þ 4, þ 7 and þ 12, beginning 24 h after completing the PBSC infusion.
Altogether, the transplant ran an uneventful course; neutrophil engraftment 40. 9 /L. Analysis of chimerism was performed by studying STR polymorphisms from BM cells, which indicated that on day þ 65, 95% of the BM cells were derived from the donor (mixed chimerism), whereas on day þ 165, 100% of the cells were derived from the donor (full donor chimerism).
Under the given circumstances, a number of procedural alternatives for donor HSC harvest were considered for our patient, but most were too lengthy in terms of the time required. PBSC mobilization with G-CSF generally requires at least 5-6 days for completion, and about 30% of the time, apheresis on two consecutive days is needed.
A repeat attempt at donor oropharyngeal intubation was also entertained but promptly rejected, because of the fear of traumatic re-bleeding. It was felt that an adequate waiting period was appropriate to avoid complications, which made this option inadvisable. For the same reason, the use of spinal or epidural anesthesia to harvest BM seemed untenable. Spinal block in the prone position may lead to respiratory insufficiency and warrant oropharyngeal intubation on an emergency basis.
The chief objection to the above harvesting strategies was their potential for prolonging the critical interval between completion of recipient conditioning and HSC infusion. The role of the time interval between the end of conditioning and cell infusion has been addressed in animal models, whereas data in humans are not available. The general conclusion that can be drawn from HSC transplants in animals is that delaying infusion for more than 4 days can lead to a substantial risk of nonengraftment.
In fact, in mice models, a delay longer than 4 days results in a low engraftment rate after a wide range of TBI doses, even though a limited delay between the end of conditioning and cell infusion may have a beneficial effect on engraftment 7 and on acute GVHD rate. 8 In addition, experimental data in dogs have shown that an interval greater than 4 days is associated with a high probability of HSC graft failure, when a haploidentical transplant is attempted after a reduced dose of TBI. 9 In this situation, the short time required for PBSC mobilization with plerixafor may be a clear advantage. In fact, plerixafor not only ensures a shorter aplasia time, but the rapidity of PBSC mobilization limiting the delay between the end of conditioning and HSC infusion to o4 days should also reduce the risk of graft rejection. In contrast, the G-CSF-induced PBSC harvest can be realized only after 5 or 6 days of G-CSF administration, and this longer delay between the end of conditioning and HSC infusion may increase the risk of rejection. 9 Plerixafor was therefore the logical and safe choice for donor and patient alike. In our patient, we had chosen to combine plerixafor and G-CSF, with both administered for 1 day. Plerixafor has been shown to augment G-CSF-induced CD34 þ cell mobilization when administered after 4 days of G-CSF 3 , and the rationale for using G-CSF with plerixafor on day þ 1 of this rescue mobilization was not to delay the start of G-CSF mobilization in the event of plerixafor failure.
Failure to harvest sufficient stem cells from either BM or mobilized peripheral blood is a rare but known impasse in HSC allogeneic transplantation. An established plan to address unexpected failures in HSC procurement is an important aspect of every transplant unit or harvest center and is an issue in the International Standards for Accreditation. 10 In the event of an insufficient BM harvest, the rapid PBSC mobilization achieved with plerixafor before apheresis can provide a solid recourse, minimizing the unanticipated infusion delay and the possible increase in risk of rejection that is associated with a prolonged delay in HSC infusion. 9 Use of G-CSF as a conventional method of PBSC mobilization leads to a delay of at least 5 days, even if G-CSF mobilization is started promptly on the day of the failed BM harvest, and this longer delay may be associated with a higher risk of graft rejection. In our donor, in whom the results of the marrow harvests were essentially untested, plerixafor was highly effective as a rescue agent for PBSC mobilization. However, in donors with a poor BM harvest because of reduced marrow cellularity, plerixafor alone would be less active, and therefore more data are needed to determine the efficacy of plerixafor in this setting.
Insufficient BM harvest can be problematic not only in the risks posed to donors and patients, but also in the limited time available for decision-making. Hence, contingency use of plerixafor should be planned and fully discussed along with other HSC procurement options, in advance of any HSC harvest failure episodes.
